Kairos Pharma Ltd. (NYSE American: KAPA) has been named a winner in the 2026 GHP Magazine Healthcare & Pharmaceutical Awards, receiving recognition as the USA leader in drug resistance development. The award highlights the company’s work in advancing cancer therapeutics designed to address treatment resistance, underscoring Kairos’ focus on extending the effectiveness of existing cancer therapies through innovative drug resistance-targeting approaches.
The company’s lead candidate, ENV-105, is an antibody that targets CD105—a protein identified as a key driver of resistance and disease relapse in response to standard therapy. By targeting CD105, ENV-105 aims to reverse drug resistance and restore the effectiveness of standard therapies across multiple cancer types. Currently, ENV-105 is in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for non-small cell lung cancer, addressing significant unmet medical needs. As of the date of the press release, ENV-105 has not been approved as safe or effective by the United States Food and Drug Administration or any other comparable foreign regulator.
Based in Los Angeles, California, Kairos Pharma is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. The recognition from GHP Magazine underscores the importance of addressing drug resistance, a major challenge in oncology that limits the efficacy of current treatments. The award may increase visibility for Kairos Pharma and its pipeline, potentially attracting investor interest and partnerships.
For more details on the award, the full press release is available at https://ibn.fm/WuBOf. Additional news and updates regarding KAPA can be found in the company’s newsroom at https://ibn.fm/KAPA.